Bioequivalence of Terazosin Hydrochloride Tablets in Healthy Volunteers

LIU Jian1 WU Li-hua1 HU Xing-jiang1 WU Guo-lan1 ZHOU Hui-li1 SHENTU Jian-zhong1

(1.Research Center of Clinical Pharmacy, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China 310000)
【Knowledge Link】bioequivalence; postural hypotension

【Abstract】 OBJECTIVE To evaluate the bioequivalence of test and reference preparations of Terazosin Hydrochloride Tablets in healthy male volunteers. METHODS This is an open random and two-way crossover clinical trial involved 18 healthy male subjects. The volunteers were randomly divided into two groups. They were given a single oral dose of test and reference preparations of Terazosin Hydrochloride Tablets (2 mg for each). The plasma concentrations of terazosin were determined by LC-MS/MS. Pharmacokinetic parameters were obtained using DAS2.0 program. RESULTS The main pharmacokinetic parameters of Terazosin Hydrochloride Tablets test and reference preparations were as follows: the median (min, max) of tmax was 1.00 (0.25, 2.00) h and 0.75 (0.50, 4.00) h; ρmax was (49.72 ± 9.86) and (61.66 ± 18.37) ng·mL−1; AUC0-t was (516.35 ± 107.33) and (616.58 ± 118.48) ng·h·mL−1; AUC0-∞ was (532.62 ± 112.42) and (634.99 ± 122.49) ng·h·mL−1; the relative bioavailability of the test preparation was (100.17 ± 13.92)%; 90% CI of AUC0-t and ρmax of the test preparation was 93.8%–105.1% and 88.3%–108.4%. No serious adverse events were observed during the trials. CONCLUSION Two kinds of Terazosin Hydrochloride Tablets are bioequivalent.

【Keywords】 terazosin; fast; bioequivalence; LC-MS/MS; pharmacokinetics;


Download this article

(Translated by SONG JF)


    [1] CHEN X Q, JIN Y Q, TANG G. New Materia Medica (新编药物学) [M]. Vol 7. Beijing: People’s Health Publishing House, 2011: 829 (in Chinese).

    [2] LIU T, ZHAO D H. Pharmacology and clinical application of terazosin [J]. World Pharm (国外医药), 1992, 13 (5): 282–284 (in Chinese).

    [3] PENG H. Comparison of efficacy of terazosin, finasteride and tamsulosin in the treatment of benign prostatic hyperplasia [J]. China Pract Med (中国实用医药), 2017, 12 (21): 111–113 (in Chinese).

    [4] CHEN Y J, ZHONG B G. Clinical observation of spironolactone and terazosin in the treatment of resistant hypertension [J]. Chin J Mod Drug App (中国现代药物应用), 2017, 11 (8): 103–106 (in Chinese).

    [5] MA N, LIU W Y, LI H D, et al. HPLC-MS/ESI determination of terazosin hydrochloride, prazosin hydrochloride and doxazosin mesyllate in human plasma [J]. Chin J Pharm Anal (药物分析杂志), 2007, 27 (10): 1548–1552 (in Chinese).

    [6] ZHANG L, WU Y Z, XU H Y, et al. Pharmacokinetics and bioequivalence of terazosin orally disintegrating tablet [J]. J Shenyang Pharm Uni (沈阳药科大学学报), 2011, 28 (9): 740–744 (in Chinese).

    [7] CHEN J, LU W, GAO K P, et al. Studies on the bioequivalence of domestic terazosin tablet in healthy volunteers [J]. Chin Pharm J (中国药学杂志), 2003, 38 (6): 446–448 (in Chinese).

This Article


CN: 11-2162/R

Vol 54, No. 18, Pages 1504-1507

September 2019


Article Outline



  • 1 Materials and methods
  • 2 Results
  • 3 Discussion
  • References